OOIR: Observatory of International Research

Papers

(The H4-Index of Hypertension Research is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial	88
Renal denervation: basic and clinical evidence	50
Systemic inflammation markers and the prevalence of hypertension: A NHANES cross-sectional study	47
Seasonal variation in blood pressure: current evidence and recommendations for hypertension management	43
Effects of renal denervation on blood pressures in patients with hypertension: a systematic review and meta-analysis of randomized sham-controlled trials	43
Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study	43
Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease	42
Novel therapeutics for the treatment of hypertension and its associated complications: peptide- and nonpeptide-based strategies	41
Hypertensive disorders of pregnancy: definition, management, and out-of-office blood pressure measurement	40
Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction	39
Nighttime home blood pressure as a mediator of N-terminal pro-brain natriuretic peptide in cardiovascular events	37
Prevalence of mild cognitive impairment in patients with hypertension: a systematic review and meta-analysis	35
Brachial-ankle pulse wave velocity and prognosis in patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis	34
Impact of the COVID-19 pandemic on blood pressure control: a nationwide home blood pressure monitoring study	33
A Japan nationwide web-based survey of patient preference for renal denervation for hypertension treatment	32
Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial	32
Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism	32
Concept, study design, and baseline blood pressure control status of the nationwide prospective HI–JAMP study using multisensor ABPM	30
Sleep and cardiovascular outcomes in relation to nocturnal hypertension: the J-HOP Nocturnal Blood Pressure Study	29
Angiotensin receptor-neprilysin inhibitors: Comprehensive review and implications in hypertension treatment	28
Renal denervation based on experimental rationale	28
The effect of an mRNA vaccine against COVID-19 on endothelial function and arterial stiffness	27
Role of the microbiota in hypertension and antihypertensive drug metabolism	27
Difference between morning and evening home blood pressure and cardiovascular events: the J-HOP Study (Japan Morning Surge-Home Blood Pressure)	26
Long COVID and hypertension-related disorders: a report from the Japanese Society of Hypertension Project Team on COVID-19	26

Effect of esaxerenone on nocturnal blood pressure and natriuretic peptide in different dipping phenotypes